At Cellular Analytics, we are deploying a proven and proprietary microfluidic platform (CytoFind™) optimized for the detection of rare circulating tumor cells. The technology is now implemented into the development of a cancer liquid biopsy test that will predict patient response to targeted therapy.


Cellular Analytics' proprietary microfluidic platform evaluates protein expression on single circulating tumor cells. It is the only technology capable of quantitatively detecting immuno-oncology sensitivity markers “on-chip” at the single-cell level.

Nature Chemistry

"Single Cell mRNA Cytometry via Sequence-Specific Nanoparticle Clustering and Trapping." M. Labib, R.M. Mohamadi, M. Poudineh, S.U. Ahmed, I. Ivanov, C.L. Huang, M. Moosavi, E.H. Sargent, S.O. Kelley Nature Chemistry, 2018, 10, 489-495. Link

Nature Biomedical Engineering

“Profiling Circulating Tumour Cells and Other Biomarkers of Invasive Cancers.”M. Poudineh, E.H. Sargent, K. Pantel, S.O. Kelley Nature Biomedical Engineering, 2018, 2, 74-82. Link

Nature Nanotechnology

“Tracking the Dynamics of Circulating Tumor Cell Phenotypes Using Nanoparticle-Mediated Magnetic Ranking.” M. Poudineh, P.M. Aldridge, S. Ahmed, B.J. Green, L. Kermanshah, V. Nguyen, C. Tu, R.M. Mohamadi, R.K. Nam, A. Hansen, S.S. Sridhar, A. Finelli, N.E. Fleshner, A.M. Joshua,  E.H. Sargent,  S.O. Kelley Nature Nanotechnology, 2017, 12, 274-282. Link


MaRS Centre - West Tower, 661 University Ave,

Suite 1300, Toronto, ON, M5G 0B7

© 2019 by Cellular Analytics.